tbuckley/cabot-search huggingface dataset:
Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Authors: J.K. Killian, D.C. Pavlick, E.S. Sokol, M. Montesion, D.X. Jin, B. Kaplan, D. Lin, J.-A. Vergilio, J.A. Elvin, N. Ngo, E. Severson, S. Ramkissoon, D. Duncan, C. Edgerly, A. Hemmerich, G.M. Frampton, G. Bratslavsky, V.A. Miller, S.M. Ali, J.S. Ross
Journal: Annals of Oncology (2019)
Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Authors: T. Alcindor, T. Opu, C. Mueller, V. Marcus, P.-O. Fiset, S. Camilleri-Broet, G. Artho, J. Asselah, M. Vanhuyse, M. Hickeson, A. Awan, Z. Koulouris, L. Ferri
Journal: Annals of Oncology (2019)
Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumours: A comparative oncology trial
Authors: F. Riccardo, L. Tarone, G. Barutello, M. Arigoni, D. Giacobino, S. Iussich, S. Occhipinti, S. Ferrone, P. Buracco, F. Cavallo
Journal: Annals of Oncology (2019)
Cardiomyocyte Homeodomain-Interacting Protein Kinase 2 Maintains Basal Cardiac Function via Extracellular Signal-Regulated Kinase Signaling
Authors: Yuanjun Guo, Jennifer Y. Sui, Kyungsoo Kim, Zhentao Zhang, Xiaoyan A. Qu, Young-Jae Nam, Robert N. Willette, Joey V. Barnett, Bjorn C. Knollmann, Thomas Force, Hind Lal
Journal: Circulation (2019)

Background: Cardiac kinases play a critical role in the development of heart failure, and represent potential tractable therapeutic targets. However, only a very small fraction of the cardiac kinome has been investigated. To identify novel cardiac kinases involved in heart failure, we used an integrated transcriptomics and bioinformatics analysis and identified Homeodomain-Interacting Protein Kinase 2 (HIPK2) as a novel candidate kinase. The role of HIPK2 in cardiac biology is unknown. Methods: We used the Expression2Kinase algorithm for the screening of kinase targets. To determine the role of HIPK2 in the heart, we generated cardiomyocyte (CM)-specific HIPK2 knockout and heterozygous mice. Heart function was examined by echocardiography, and related cellular and molecular mechanisms were examined. Adeno-associated virus serotype 9 carrying cardiac-specific constitutively active MEK1 (TnT-MEK1-CA) was administrated to rescue cardiac dysfunction in CM-HIPK2 knockout mice. Results: To our knowledge, this is the first study to define the role of HIPK2 in cardiac biology. Using multiple HIPK2 loss-of-function mouse models, we demonstrated that reduction of HIPK2 in CMs leads to cardiac dysfunction, suggesting a causal role in heart failure. It is important to note that cardiac dysfunction in HIPK2 knockout mice developed with advancing age, but not during development. In addition, CM-HIPK2 knockout mice and CM-HIPK2 heterozygous mice exhibited a gene dose-response relationship of CM-HIPK2 on heart function. HIPK2 expression in the heart was significantly reduced in human end-stage ischemic cardiomyopathy in comparison to nonfailing myocardium, suggesting a clinical relevance of HIPK2 in cardiac biology. In vitro studies with neonatal rat ventricular CMscorroborated the in vivo findings. Specifically, adenovirus-mediated overexpression of HIPK2 suppressed the expression of heart failure markers, NPPA and NPPB , at basal condition and abolished phenylephrine-induced pathological gene expression. An array of mechanistic studies revealed impaired extracellular signal-regulated kinase 1/2 signaling in HIPK2-deficient hearts. An in vivo rescue experiment with adeno-associated virus serotype 9 TnT-MEK1-CA nearly abolished the detrimental phenotype of knockout mice, suggesting that impaired extracellular signal-regulated kinase signaling mediated apoptosis as the key factor driving the detrimental phenotype in CM-HIPK2 knockout mice hearts. Conclusions: Taken together, these findings suggest that CM-HIPK2 is required to maintain normal cardiac function via extracellular signal-regulated kinase signaling.
Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Authors: N. Jimenez, O. Reig, R. Montalbo, M. Milà-Guasch, L. Nadal-Dieste, I. Victoria, A. Font, A. Rodriguez-Vida, J. Carles, C. Suárez, M. Domenech, N. Sala-González, P.L. Fernández, A. Prat, M. Marín-Aguilera, B. Mellado
Journal: Annals of Oncology (2019)
Adverse events in oncology and haemato-oncology inpatients of Swiss hospitals: A descriptive study
Authors: A. Gerber, A.M. da Silva Lopes, N. Szüts, V. Ribordy-Baudat, A. Ebneter, C. Perrinjaquet, D. Betticher, M. Cote, M.A. Duchosal, C. Brennan, S. Decosterd, S. Peters, R. Koelliker, F. Ninane, M.-M. Jeitziner, S. Colomer-Lahiguera, P.-Y. Dietrich, M. Simon, M.-E. Gaignard, M. Eicher
Journal: Annals of Oncology (2019)
Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Authors: S. Recalde, V. Quiroga, S. del Barco, C. Falo, J. Dorca, M. Margeli, A. Stradella, T. Soler, I ruel Te García, G. Viñas, A. Fernandez, R Villanueva Vázquez, A. Vethencourt, M Romeo Marin, M. Gil-Gil
Journal: Annals of Oncology (2019)
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Authors: Anuhar Chaturvedi, Ramya Goparaju, Charu Gupta, Julia Weder, Thomas Klünemann, Michelle Maria Araujo Cruz, Arnold Kloos, Kerstin Goerlich, Renate Schottmann, Basem Othman, Eduard A. Struys, Heike Bähre, Denis Grote-Koska, Korbinian Brand, Arnold Ganser, Matthias Preller, Michael Heuser
Journal: Leukemia (2019)
Helen Salisbury: The confident gatekeeper
Authors: Helen Salisbury
Journal: BMJ (2019)

One of the roles assigned to GPs is that of “gatekeeper” to the NHS. We are, according to one interpretation, the barrier that holds back a mass of patients who might otherwise swamp hospital clinics with an unsorted array of ill defined symptoms. Rejecting this caricature, we are better seen as experts who can treat most ailments and prevent many more, referring on to our hospital colleagues only those patients who need specialist investigation or surgery.

However we view it, GPs are credited in this role as being a source of cost …
Impedance and Histologic Characteristics of the Sub-Laryngeal Esophagus Distinguish Eosinophilic Esophagitis From Other Esophageal Disorders
Authors: Yash A. Choksi, Jasmine Chaparro, Michael Blanco, Rohit Sharda, Shabnam Sarker, Sarah Ferguson, Tina Higginbotham, Girish Hiremath, Frank Revetta, M. Kay Washington, Christopher S. Williams, Michael F. Vaezi
Journal: Clinical Gastroenterology and Hepatology (2019)
Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results
Authors: Robert J MacInnis, Yuyan Liao, Julia A Knight, Roger L Milne, Alice S Whittemore, Wendy K Chung, Nicole Leoce, Richard Buchsbaum, Nur Zeinomar, Gillian S Dite, Melissa C Southey, David Goldgar, Graham G Giles, Sue-Anne McLachlan, Prue C Weideman, Stephanie Nesci, Michael L Friedlander, Gord Glendon, Irene L Andrulis, Esther M John, Mary B Daly, Saundra S Buys, Kelly Anne Phillips, John L Hopper, Mary Beth Terry
Journal: JNCI Journal of the National Cancer Institute (2019)

The performance of breast cancer risk models for women with a family history but negative BRCA1 and/or BRCA2 mutation test results is uncertain. We calculated the cumulative 10-year invasive breast cancer risk at cohort entry for 14 657 unaffected women (96.1% had an affected relative) not known to carry BRCA1 or BRCA2 mutations at baseline using three pedigree-based models (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, BRCAPRO, and International Breast Cancer Intervention Study). During follow-up, 482 women were diagnosed with invasive breast cancer. Mutation testing was conducted independent of incident cancers. All models underpredicted risk by 26.3%-56.7% for women who tested negative but whose relatives had not been tested (n = 1363; 63 breast cancers). Although replication studies with larger sample sizes are needed, until these models are recalibrated for women who test negative and have no relatives tested, caution should be used when considering changing the breast cancer risk management intensity of such women based on risk estimates from these models.
Complications of thermal ablation of hepatic tumors: Comparison of radiofrequency and microwave techniques.
Authors: Xiang Jing, Jianmin Ding, Jibin Liu, Yandong Wang, Fengmei Wang, Yijun Wang, Zhi Du
Journal: Journal of Clinical Oncology (2013)

e15040 Background: The efficacy and safety of radiofrequency ablation (RFA) have been reported in the literatures, which are considered as frontline choice for treatment of liver cancer. Recently, microwave ablation (MWA) has emerged and gained great attention over RFA. However, in comparison to RFA, the safety of MWA for treatment of liver cancer has not been fully reported in the literatures. Studies with large clinical data sets are still needed to understand the technique and avoid the complications. The objective of this study was to retrospectively investigate the common complications of thermal ablations of liver tumors using both RFA and MWA techniques, and compare the safety between these two procedures. Methods: This retrospective study protocol was approved by our institutional ethics committee to allow investigators to review the existing patient’s medical records. A total of 879 patients with hepatic tumors underwent thermal ablation. There were 323 cases having the RFA procedures and 556 cases having MWA procedures. The complications of thermal ablations of liver tumors were compared using both RFA and MWA techniques. Results: A total of 1,030 thermal ablation sessions was performed in 879 patients with a total of 1,652 tumors. There were 323 patients with 562 tumors received a total of 376 RFA with averaged 1.16±0.48 sessions per patient. The other 556 patients with 1,090 tumors received a total of 654 MWA with averaged1.18±0.51 sessions per patient. The mortality rates were 0.31% (1/323) and 0.36% (2/556) in RFA and MWA group. In RFA and MWA group, the major complication rates were 3.5% (13/376) and 3.1% (20/654) (Table 1), meanwhile the minor complication rates were 5.9% (22/376) and 5.7% (37/654). There was no statistical significant difference for the mortality rates, the major complications, the minor complications between the RFA and MWA groups (P&gt;0.05). Conclusions: Thermal ablation therapy in the treatment of liver cancers is relatively safe with low mortality and low incidence of serious complications. The types and incidences of complications caused by RFA and MWA are similar and comparable for safety consideration in clinical settings.
Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)
Authors: M.-O. Grimm, M. Schmidinger, I. Duran Martinez, G. Schinzari, E. Esteban, M. Schmitz, U. Schumacher, G. Baretton, P. Barthelemy, B. Melichar, N. Charnley, D. Schrijvers, L. Albiges
Journal: Annals of Oncology (2019)
Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Authors: J. Beaziz, M. Battistella, J. Delyon, C Le Maignan, O. Marco, D. Kérob, C Pages Laurent, L. Da Meda, C. Farges, N. Basset-Seguin, C. Lebbe, B. Baroudjian
Journal: Annals of Oncology (2019)
18F-FDG PET/CT Findings of Ovarian Mesothelioma
Authors: Rui Sun, Yue Chen, Zhanwen Huang
Journal: Clinical Nuclear Medicine (2019)

Abstract Ovarian mesothelioma is a rare and aggressive tumor. Early diagnosis of the disease is difficult, delaying effective treatment. Here we report a 50-year-old woman who was referred for an 18 F-FDG PET/CT imaging to assess her newly detected left ovarian mass. The images not only demonstrated a hypermetabolic mass in the left ovary, but also several hepatic low densities with increased FDG uptake, which suggested ovarian malignancy with hepatic metastases. Mesothelioma was diagnosed histopathologically following the biopsy. Our case demonstrates PET/CT findings observed in ovarian mesothelioma.
Abstract P072: Most U. S. adults do not meet dietary guidelines for sodium and potassium, National Health and Nutrition Examination Survey, 2003-2008
Authors: Mary Cogswell, Zefeng Zhang, Alicia Carriquiry, Janelle Gunn, Elena Kuklina, Sharon Saydah, Quanhe Yang, Alanna Moshfegh
Journal: Circulation (2012)

Introduction: The 2010 Dietary Guidelines recommend Americans reduce sodium intake and choose foods that contain potassium to decrease the risk of hypertension and subsequent heart disease and stroke. Limited data exist on the proportion of U.S. adults who meet the 2010 Dietary Guidelines for Americans for sodium and potassium. Hypothesis: We hypothesized that the majority of U.S. adults do not meet the 2010 Dietary Guidelines for sodium and potassium. Methods: We used 24-hour dietary recalls and other data from 12,581 non-institutionalized adults aged &gt; 20 years who participated in the National Health and Nutrition Examination Survey in 2003–2008. We estimated the distributions of usual daily sodium and potassium intakes by sociodemographic and health characteristics relative to the 2010 Dietary Guidelines. Health characteristics included hypertension (use of anti-hypertensive medications, systolic blood pressure &gt; 140 mm Hg or diastolic blood pressure &gt; 90 mm Hg), diagnosed (self report) or undiagnosed diabetes (fasting plasma glucose &gt; 126 mg/dL or glycohemoglobin &gt; 6.5%), and chronic kidney disease (defined by estimated glomerular filtration rate &lt;60 mL/min/1.73 m 2 or urine albumin-creatinine ratio &gt; 30 mg/g). Estimates of usual sodium and potassium intake were adjusted for within-individual, day-to-day variation using measurement error models (Software for Intake Distribution Estimation) with two-24 hour diet recalls on 89.6% of our sample. Standard errors and ninety-five percent confidence intervals were assessed using jack-knife replicate weights. Results: Overall, 99.4% (95% confidence interval [CI], 99.3%, 99.5%) and 90.7% (89.6%, 91.8%) of U.S. adults consumed &gt;1500 mg and &gt; 2300 mg sodium daily, respectively. Among U.S. adults recommended to reduce sodium to 1500 mg daily (i.e., African-Americans, age &gt;51 years, or persons with hypertension, diabetes, or chronic kidney disease), 98.8% (98.4%, 99.2%) consumed &gt;1500 mg daily and 60.4% consumed more than double the recommendation, &gt;3000 mg daily. Regardless of sex, age, race-ethnicity, income, education, body mass index, hypertension, diabetes, or chronic kidney disease more than 84% of adults consumed sodium in excess of guidelines. Overall, less than 2% of U.S. adults and ∼5% of U.S. men consumed &gt; 4700 mg potassium daily, i.e., meeting 2010 Dietary Guidelines for potassium. Conclusions: Limitations of our analyses include estimation of nutrient intake from 24-hour diet recalls and inability to account for salt added at the table or from supplements, potentially resulting in an underestimation of sodium and potassium intake. In conclusion, most U.S. adults consume too much sodium and too little potassium.
A phase I trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumour mutations
Authors: P. Twardowski, M.L. Johnson, M. Stein, U. Vaishampayan, M.L. Gillison, L. McNeil, L. Dowal, D. DeOliveira, M. Jain, J. Price, R. Hernandez, A. DeCillis, N. Singh, T. Davis, J. Flechtner, R.B. Cohen
Journal: Annals of Oncology (2019)
Consultant who viewed images of child sexual abuse receives suspended sentence
Authors: Clare Dyer
Journal: BMJ (2019)

A consultant anaesthetist who said he turned to viewing images of child sexual abuse to combat stress from working in an intensive care unit has been sentenced to six months in prison, suspended for two years.

Richard Johnson, 54, had been collecting images of children being sexually abused for eight years when his offending was discovered by police after he mistakenly uploaded an image on to the social media website Pinterest.

West Yorkshire police found that he had more than 54 000 sexual images of children on four computer devices, of which 335 were category A, the most extreme category. Of the category A images, 69 were videos.

He pleaded guilty …
Re-introduction of T-VEC monotherapy in recurrent stage IIIB/C-IVM1a melanoma is effective
Authors: V. Franke, E.H.A. Stahlie, B. van der Hiel, B.A. van de Wiel, M W J M Wouters, W. Van Houdt, A.C.J. van Akkooi
Journal: Annals of Oncology (2019)
Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Authors: F Costa Svedman, I. Das, R. Tuominen, E.D. Ramqvist, J. Hansson, V. Höiom, S Egyhazi Brage
Journal: Annals of Oncology (2019)
HGG-13. SURVIVAL OUTCOMES OF CHILDREN AND ADOLESCENTS WITH BI-THALAMIC GLIOMAS: THE SOUTH THAMES NEURO-ONCOLOGY UNIT EXPERIENCE
Authors: Ajla Wasti, Tineke Boesten, Karen Powell, Lynley Marshall, Sucheta Vaidya, Paola Angelini, Henry Mandeville, Frank Saran, Julia Chisholm, Chris Jones, Chris Chandler, Simon Stapleton, Leslie Bridges, Safa Al-Sarraj, Fernando Carceller
Journal: Neuro-Oncology (2018)

Bithalamic gliomas (BG) are rare brain tumours typically with a dismal prognosis, irrespective of histological grading. Limited information is available on survival outcomes for children and adolescents with BG. Review of patients aged ≤18 years with clinico-radiological diagnosis of BG between 1995-2017 at our institution. Clinical, radiological, histological and outcome data were collected. Log-rank test was used for survival analyses. Sixteen eligible patients were identified (male-female ratio 1:1). Median age was 9.1 years (range, 0.9-17.9). Twelve (75%) patients had hydrocephalus at initial presentation. Fourteen (88%) underwent surgery (debulking: 1; biopsy: 13). Histology was consistent with low grade glioma (LGG; n=6), high grade glioma (HGG; n=6) or inconclusive (n=2). Methylation profiling was available in 5 cases: K27M-mutant (n=2) and histone 3 wild-type (n=3). One patient died prior to initiation of treatment from intratumoural haemorrhage. Thirteen (81%) patients received radiotherapy: alone (n=2), combined with temozolomide (n=8) or followed by other chemotherapy regimens (n=3). Two patients who were not irradiated received vincristine/carboplatin. Median progression-free (PFS) and overall survival (OS) for the whole cohort were 8.3 months (95%CI, 2.3-14.3) and 13.8 months (95%CI, 10.5-17.1), respectively. There was no difference in median PFS or OS between patients diagnosed as LGG or HGG (p=0.769 and p=0.512, respectively). Our data is consistent with prior reports showing poor survival of patients with BG, regardless of histological grade. Novel approaches based on the underlying biology of these tumours are desperately needed for this subset of patients.
Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial phase Ib results
Authors: D. Berz, A. Spira, S.M. Gadgeel, I.C. Anderson, J.W. Goldman, J. Thompson, T. Foster, Y.L. Pritchett, C.G. Cisneros, C. Li, J.A. Sorrentino, R. Malik, A.P. Beelen
Journal: Annals of Oncology (2019)
It’s not only about weight loss: Tackling pancreatic cancer-associated cachexia
Authors: A.L.V. Matos, L. Fernandes, H. Cunha, J.A. Graca, J. Barata, M.T. Neves, F.R. Alves, J. Pereira, F.A.S. Ferreira, A. Freire Coelho, M. Malheiro, M.S. Mesquita Pinto, M. Fontes e Sousa, A. Placido, C. Mourão, A.M. Henriques Martins
Journal: Annals of Oncology (2019)
Abstract 1825: Abnormal ECG Markers suggest that Accentuated Intracardiac Conduction Delay is The Common and Distinguishing Feature of Patients with Spontaneous Type 1 ECG or SCN5A Mutation in Brugadas Syndrome
Authors: Juliane Theilade, Raffaella Bloise, Janny Nastoli, Elena Ronchetti, S. Facchinetti, Tom Rossenbacker, Carlo Napolitano, Silvia G Priori
Journal: Circulation (2007)

The conclusive diagnosis of Brugada Syndrome (BrS) is established in patients (pts) with spontaneous type 1 ECG or in carriers of a loss of function SCN5A mutation. We carried out a systematic analysis of ECG recordings in BrS pts to test the hypothesis that the presence of intraventricular (Intra-Ven) and atrioventricular (A-Ven) conduction delay is the distinguishing common feature of pts with SCN5A mutations (Mut+) and in pts with a spontaneous type 1 ECG pattern (spont-ECG). We assessed the following 5 ECG parameters: late potentials (quantified as RMS at 40 Hz), aVR sign (relative size of the R and q waves in aVR), QRS complex fragmentation (defined as an additional R′ or notching of the of S wave), PQ and QRS duration. We studied 200 consecutive BrS pts to define whether the prevalence of ECG markers correlate with 1) the presence of a SCN5A mutation (Mut+) or 2) the presence of a spontaneous type 1 pattern ECG (spont-ECG). Results are summarized in the table . Interestingly, Mut+ not only presented prolonged PQ (p&lt;0.003 vs Mut÷) as previously reported but more significantly they showed the presence of abnormal markers of intraventricular conduction (QRS duration, aVR sign and late potentials). Similarly, also the presence of a spont-ECG was associated with prolonged PQ and QRS intervals and with late potentials. Based on our ECG analysis we propose that Brugada syndrome is a disease characterized by impairment of A-Ven and Intra-Ven conduction, the presence of a mutation in the SCN5A gene and, the presence of a spontaneous type 1 ECG identify patients with accentuated conduction defects. These findings suggest that the presence of interventricular conduction delay is a landmark of BrS and should be considered as diagnostic markers in BrS.
Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): A French nationwide retrospective cohort (UNIVOC Study)
Authors: C. Chouaid, M Giaj Levra, R. Corre, C. Calvet, A.-F. Gaudin, V. Grumberg, R. Jolivel, B. Jouaneton, J.-B. Assié, F.-E. Cotté
Journal: Annals of Oncology (2019)
Unique Effects of p53−/− Leukemic Cells On Mesenchymal Stromal Cell Gene Expression Profile in Vitro
Authors: Xiaoyang Ling, Ye Chen, Peter P. Ruvolo, Vivian Ruvolo, Zhiqiang Wang, Min Zhang, Yuexi Shi, Marina Konopleva, Richard E Davis, Michael Andreeff
Journal: Blood (2012)
An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK study
Authors: D.R. Gandara, W. Zou, J. Jiang, S. Yaung, F. Fuhlbrück, J. Wu, M. Peterson, J. Palma, M. Ballinger, E. Peters, D. Shames, N. Patil
Journal: Annals of Oncology (2019)
POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Authors: E. Van Cutsem, T. Golan, P. Hammel, M. Reni, T. Macarulla, M.J. Hall, J.O. Park, D. Hochhauser, D. Arnold, D.-Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E.M. O’Reilly, D. McGuinness, K.Y. Cui, K. Schlienger, G.Y. Locker, H.L. Kindler
Journal: Annals of Oncology (2019)
Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Authors: L.A. Moukarzel, A. Stylianou, M. Wu, S.P. Nobre, N.R. Abu-Rustum, V. Broach, D.D. Giri, N.M. Iyengar, B. Weigelt, V. Makker
Journal: Annals of Oncology (2019)
Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
Authors: J.H. Strickler, T. Zemla, F.-S. Ou, A. Cercek, C. Wu, F.A. Sanchez, J. Hubbard, B. Jaszewski, L. Bandel, B. Schweitzer, D. Niedzwiecki, N. Kemeny, P.M. Boland, K. Ng, T. Bekaii-Saab
Journal: Annals of Oncology (2019)
Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
Authors: F. Longo Munoz, M. Jorge Fernandez, R. Yaya Tur, S. Diaz, M. Ortega, T. Dilla, A. Molero, J.M. Cervera
Journal: Annals of Oncology (2019)